When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Câncer de ovário

Última revisão: 12 Dec 2025
Última atualização: 12 Mar 2025

Resumo

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • massa pélvica
  • ascite
  • derrame pleural
Full details

Other diagnostic factors

  • sintomas gastrointestinais
  • urgência urinária e polaciúria
  • duração dos sintomas >3 meses
  • distensão abdominal
  • dor ou pressão pélvica/abdominal
Full details

Risk factors

  • mutações genéticas associadas com o câncer de ovário hereditário
  • idade mais avançada
  • história familiar de câncer de ovário, câncer de mama, câncer colorretal e/ou câncer de endométrio
  • nunca usou contraceptivos orais combinados
  • nuliparidade
  • obesidade
  • terapia hormonal
  • endometriose
Full details

Diagnostic tests

1st tests to order

  • ultrassonografia pélvica
  • CA-125
  • histopatologia
Full details

Tests to consider

  • teste genético
  • PET, PET-CT ou PET/RNM
  • RNM
  • Tomografia computadorizada (TC)
  • testes de biomarcadores
Full details

Treatment algorithm

ACUTE

candidato à cirurgia, doença confirmada por histologia intraoperatória

não candidato à cirurgia, doença confirmada por biópsia

ONGOING

doença recorrente sensível à platina

doença resistente à platina recorrente ou refratária

Contributors

Authors

Sareena Singh, MD

Gynecologic Oncologist

Aultman Medical Group

Northeast Ohio Medical University

Canton

OH

Disclosures

SS declares that she has no competing interests.

Acknowledgements

Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.

Disclosures

JCC and AEA declare that they have no competing interests.

Peer reviewers

Michael P. Hopkins, MD, MEd

Chairman

Obstetrics and Gynecology

Northeast Ohio Universities of Medicine (NEOMED)

Rootstown

OH

Disclosures

MPH declares that he has no competing interests.

Ritu Salani, MD

Gynecologic Oncology Fellow

Johns Hopkins Medical Institutions

Baltimore

MD

Disclosures

RS declares that she has no competing interests.

Susan A. Davidson, MD

Associate Professor

Chief, Gynecologic Oncology

Department of Obstetrics & Gynecology (UCD)

University of Colorado Cancer Center

Aurora

CO

Disclosures

SAD declares that she has no competing interests.

Khadra Galaal, MBChB, MPH, MRCOG

Consultant Gynaecological Oncologist

Northern Gynaecological Oncology Centre

Queen Elizabeth Hospital

Gateshead

UK

Раскрытие информации

KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.

Jill Tseng, MD

Assistant Clinical Professor of Gynecologic Oncology

University of California, Irvine

Orange

CA

Раскрытие информации

JT declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer [internet publication].Полный текст

González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.Полный текст  Аннотация

Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025 Mar;43(7):868-91.Полный текст  Аннотация

Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.Полный текст  Аннотация

Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности